Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Nurix Therapeutics, Inc. or Alvotech because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Nurix Therapeutics, Inc. and Alvotech compare based on key financial metrics to determine which better meets your investment needs.

About Nurix Therapeutics, Inc. and Alvotech

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn’s disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Latest Biotechnology and Nurix Therapeutics, Inc., Alvotech Stock News

As of September 21, 2026, Nurix Therapeutics, Inc. had a $2.6 billion market capitalization, compared to the Biotechnology median of $269.5 million. Nurix Therapeutics, Inc.’s stock is NA in 2026, NA in the previous five trading days and up 183.28% in the past year.

Currently, Nurix Therapeutics, Inc. does not have a price-earnings ratio. Nurix Therapeutics, Inc.’s trailing 12-month revenue is $36.8 million with a -928.4% net profit margin. Year-over-year quarterly sales growth most recently was -79.6%. Analysts expect adjusted earnings to reach $3.376 per share for the current fiscal year. Nurix Therapeutics, Inc. does not currently pay a dividend.

Currently, Alvotech does not have a price-earnings ratio. Alvotech’s trailing 12-month revenue is $494.6 million with a -36.3% net profit margin. Year-over-year quarterly sales growth most recently was -20.3%. Analysts expect adjusted earnings to reach $-0.018 per share for the current fiscal year. Alvotech does not currently pay a dividend.

How We Compare Nurix Therapeutics, Inc. and Alvotech Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Nurix Therapeutics, Inc. and Alvotech’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Nurix Therapeutics, Inc. and Alvotech Stock Value Grades

Company	Ticker	Value
Nurix Therapeutics, Inc.	NRIX	F
Alvotech	ALVO	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Nurix Therapeutics, Inc. has a Value Score of 2, which is Ultra Expensive. Alvotech has a Value Score of 14, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Nurix Therapeutics, Inc. or Alvotech has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Nurix Therapeutics, Inc. or Alvotech is the better investment when it comes to value.

Nurix Therapeutics, Inc. and Alvotech’s Momentum Grades

Company	Ticker	Momentum
Nurix Therapeutics, Inc.	NRIX	A
Alvotech	ALVO	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Nurix Therapeutics, Inc. has a Momentum Score of 97, which is Very Strong. Alvotech has a Momentum Score of 77, which is Strong.

The Momentum Grade Winner: Nurix Therapeutics, Inc.

As you can clearly see from the Momentum Grade breakdown above, Nurix Therapeutics, Inc. is considered to have stronger momentum compared to Alvotech. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Nurix Therapeutics, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Nurix Therapeutics, Inc. and Alvotech’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Nurix Therapeutics, Inc.	NRIX	C
Alvotech	ALVO	F

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Nurix Therapeutics, Inc. has a Earnings Estimate Score of 59, which is Neutral. Alvotech has a Earnings Estimate Score of 5, which is Very Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Nurix Therapeutics, Inc. or Alvotech has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Nurix Therapeutics, Inc. or Alvotech is the better investment when it comes to estimate revisions.

Other Nurix Therapeutics, Inc. and Alvotech Grades

In addition to Momentum, Estimate Revisions and Value, A+ Investor also provides grades for Growth and Quality.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Nurix Therapeutics, Inc. and Alvotech pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Nurix Therapeutics, Inc. or Alvotech Stock?

Overall, Nurix Therapeutics, Inc. stock has a Value Score of 2, Momentum Score of 97 and Estimate Revisions Score of 59.

Alvotech stock has a Value Score of 14, Momentum Score of 77 and Estimate Revisions Score of 5.

Comparing Nurix Therapeutics, Inc. and Alvotech’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.